摘要Background Acute myocardial infarction(AMI),one of the most critical cardiovascular emergencies,carries a high mortality rate due to progressive cardiac dysfunction caused by myocardial ischemia.Percutaneous coronary intervention(PCI)is an effective treatment for AMI,rapidly restoring blood flow,reducing myocardial injury,and mitigating adverse remodeling.However,reperfusion injury and ventricular remodeling post-PCI may still lead to heart failure.Recent studies highlighted the cardioprotective effects of sodium-glucose cotransporter-2(SGLT-2)inhibitors,particularly dapagliflozin,which improves myocardial energetics,reduces inflammation,and attenuates adverse remodeling.However,high-quality evidence on its early application following primary PCI in AMI re-mains limited.In this study,we aimed to evaluated the clinical utility of dapagliflozin in AMI management.Meth-ods This study retrospectively analyzed the clinical data of 100 patients with AMI undergoing emergency PCI ad-mitted to our hospital between June 2022 and June 2024.They were randomly divided into observation group(n=50)and control group(n=50).The control group received standard post-PCI medication(antiplatelet and lipid-low-ering therapy),while the observation group received additional dapagliflozin.Cardiac function parameters,serolog-ical markers,and the incidence of major adverse cardiovascular events(MACE)were compared between the two groups.Results After 14 days of treatment,observation group exhibited significantly lower left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)(P<0.05)and higher left ventricu-lar ejection fraction(LVEF)(P<0.05)compared to control group.Additionally,the level of myocardial injury mark-ers[creatine kinase-MB(CK-MB),cardiac troponin I(cTnI),and brain natriuretic peptide(BNP)]were significant-ly lower in observation group(P<0.05).However,there was no significant difference in the incidence of MACE be-tween the two groups(P>0.05).Conclusions The combination of dapagliflozin with standard post-PCI therapy improves cardiac function and reduces the level of myocardial injury markers in AMI patients,though it does not significantly affect the short-term incidence of adverse cardiovascular events.[S Chin J Cardiol 2025;26(1):36-41]